reports
Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the A...
Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer’s Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting Late-breaking oral presentation of results from the positive pivotal ACCORD-2 Phase 3 trial of AXS-05 in Alzheimer’s disease agitation Presentation featuring network meta-analysis of SYMBRAVO® versus oral CGRPs NEW YORK, April 04, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treat...
Texas Pacific Land Corp: 1 director
A director at Texas Pacific Land Corp bought 10 shares at 1,331.210USD and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...
Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proo...
Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (MDD) with and without Excessive Daytime Sleepiness (EDS) Results support continued development in MDD with concomitant EDS; Phase 3 trial planned in 2025 Approximately 50 percent of MDD patients experience EDS1, highlighting high unmet need NEW YORK, April 01, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced results ...
Ryman Hospitality Properties, Inc. Announces First Quarter 2025 Earnin...
Ryman Hospitality Properties, Inc. Announces First Quarter 2025 Earnings Conference Call – Friday, May 2, 2025, 12 p.m. ET NASHVILLE, Tenn., March 31, 2025 (GLOBE NEWSWIRE) -- Ryman Hospitality Properties, Inc. (NYSE: RHP) (the "Company”), a leading lodging and hospitality real estate investment trust that specializes in upscale convention center resorts and entertainment experiences, announced today that it will release its first quarter 2025 earnings results after the market closes on Thursday, May 1, 2025. Management will hold a conference call to discuss the quarter's results at 12:00...
Moody’s Ratings rates Principal’s senior debt Baa1; stable outlook
guaranteed senior unsecured debt at Baa1, stable outlook). The notes are a drawdown and dissolution of High Street Funding Trust I which is Principal's Pre-Capitalized Trust Securities (P-Caps) contingent capital facility. The proceed of the debt issuance will be used for general corporate purposes,...
Global Partners Lp: 1 director
A director at Global Partners Lp sold/sold after exercising options 15,006 shares at 52.742USD and the significance rating of the trade was 58/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's director...
Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in A...
Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint Demonstrated substantial and statistically significant improvement in ADHD symptoms as measured by the AISRS total score compared to placebo (p=0.039, primary endpoint, 150 mg solriamfetol) Statistically significant reduction in overall ADHD disease severity as measured by the CGI-S score compared to placebo (p=0.017, key secondary endpoint, 150 mg solriamfetol) Statistically significant rate of clinical response on the AISRS compared t...
SuRo Capital Corp. Reports Fourth Quarter and Fiscal Year 2024 Financi...
SuRo Capital Corp. Reports Fourth Quarter and Fiscal Year 2024 Financial Results Invests $54.5 Million in AI Infrastructure in 2024 CoreWeave, Inc., Single Largest Initial Investment in Fund’s History, Files for IPO Net Asset Value of $6.68 Per Share as of December 31, 2024 NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- (“SuRo Capital”, the “Company”, “we”, “us”, and “our”) (Nasdaq: ) today announced its financial results for the fourth quarter and fiscal year ended December 31, 2024. Net assets totaled approximately $157.6 million, or $6.68 per share, at Decembe...
Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation w...
Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Hikma Pharmaceuticals USA NEW YORK, March 05, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has entered into a settlement agreement with Hikma Pharmaceuticals USA, Inc. (Hikma) resolving patent litigation related to Axsome’s product Sunosi® (solriamfetol). The litigation, which is pending in the United States District Court for the District of New Jersey, res...
SuRo Capital Corp. to Report Fourth Quarter and Fiscal Year 2024 Finan...
SuRo Capital Corp. to Report Fourth Quarter and Fiscal Year 2024 Financial Results on Tuesday, March 11, 2025 NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- (“SuRo Capital”) (Nasdaq: ) today announced that it will report its financial results for the quarter and fiscal year ended December 31, 2024 after the close of the U.S. market on Tuesday, March 11, 2025. Management will hold a conference call and webcast for investors at 2:00 p.m. PT (5:00 p.m. ET). The conference call access number for U.S. participants is 866-580-3963, and the conference call access number for participants outside ...
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
S&P 500 and Nasdaq 100 Testing Initial Support In last week's 2/25/25 Compass, we discussed our expectation for near-term downside as the S&P 500 and Nasdaq 100 (QQQ) displayed several bearish short-term developments. We also said it likely means at least another 2-4 weeks of consolidation, and that if the S&P 500 remains below 6100 and 6150 resistances, do not be surprised if there is a test of the bottom of the range at either 5770-5850 or 5600-5670, where we would be buyers (though we need 5...
TRV TRAVELERS COMPANIES INC.
AFL AFLAC INCORPORATED
PPL PPL CORPORATION
PFG PRINCIPAL FINANCIAL GROUP INC.
NI NISOURCE INC
NFG NATIONAL FUEL GAS COMPANY
MKL MARKEL CORPORATION
MFC. MANULIFE FINANCIAL CORPORATION
EXC EXELON CORPORATION
ERIE ERIE INDEMNITY COMPANY CLASS A
EQT EQT CORPORATION
ED CONSOLIDATED EDISON INC.
CPK CHESAPEAKE UTILITIES CORPORATION
CB CHUBB LIMITED
ALL ALLSTATE CORPORATION
FNF FIDELITY NATIONAL FINANCIAL INC. - FNF GROUP
MET METLIFE INC.
BRK.B BERKSHIRE HATHAWAY INC. CLASS B
SLF SALAFIN
CNA CNA FINANCIAL CORPORATION
UGI UGI CORPORATION
NJR NEW JERSEY RESOURCES CORPORATION
PRU2 PRUDENTIAL PLC
CINF CI GLOBAL INFRASTRUCTURE PRIVATE POOL
EQH EQUITABLE HOLDINGS INC.
CRBG COREBRIDGE FINANCIAL INC.
Ryman Hospitality Properties, Inc. Provides Investor Presentation Ahea...
Ryman Hospitality Properties, Inc. Provides Investor Presentation Ahead of Upcoming Institutional Investor Conferences NASHVILLE, Tenn., March 03, 2025 (GLOBE NEWSWIRE) -- Ryman Hospitality Properties, Inc. (NYSE: RHP) (the “Company”), a leading lodging and hospitality real estate investment trust that specializes in group-oriented, upscale convention center resorts and country music entertainment experiences, today provided an updated investor presentation ahead of its participation in two upcoming institutional investor conferences: Citi’s 30th Annual Global Property CEO Conference and ...
Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 i...
Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer’s Disease Agitation Supporting NDA Submission Supplemental New Drug Application (sNDA) submission anticipated in 3Q 2025 NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has received formal pre-New Drug Application (NDA) meeting minutes from the U.S. Food and Drug Administration (FDA) supporting a supplemental NDA (sNDA) submission for AXS-0...
Moody’s Ratings rates Principal’s new P-Caps Baa1; stable outlook
New York , February 27, 2025 – Moody's Ratings (Moody's) has assigned a Baa1 senior unsecured debt rating to the Pre-capitalized Trust Securities (P-Caps) expected to be issued by High Street Funding Trust III, a Delaware statutory trust, that will serve as a source of liquidity for Principal Financ...
Axsome Therapeutics to Participate in Upcoming Investor Conferences
Axsome Therapeutics to Participate in Upcoming Investor Conferences TD Cowen 45th Annual Health Care Conference on March 4 in Boston Leerink Partners Global Biopharma Conference on March 12 in Miami NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in two upcoming investor conferences in March: TD Cowen 45th Annual Health Care ConferenceThe Company will present on Tuesday, March 4, 2025, at 9:50 a.m. ET in...
Ryman Hospitality Properties, Inc. Announces Participation in Upcoming...
Ryman Hospitality Properties, Inc. Announces Participation in Upcoming Institutional Investor Conferences NASHVILLE, Tenn., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Ryman Hospitality Properties, Inc. (NYSE: RHP) (“RHP”), a leading lodging and hospitality real estate investment trust that specializes in group-oriented, upscale convention center resorts and country music entertainment experiences, announced today its participation in two upcoming institutional investor conferences. Mark Fioravanti, President and Chief Executive Officer, and Jennifer Hutcheson, Executive Vice President and Chief Fi...
- Wedbush Research
DPZ DOMINO'S PIZZA INC.
WDC WESTERN DIGITAL CORPORATION
TRIP TRIPADVISOR INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
RHP RYMAN HOSPITALITY PROPERTIES INC.
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
EXPE EXPEDIA GROUP INC.
CYBR CYBERARK SOFTWARE LTD.
BCRX BIOCRYST PHARMACEUTICALS INC.
AZO AUTOZONE INC.
AXTI AXT INC.
AAP ADVANCE AUTO PARTS INC.
OSTK OVERSTOCK.COM INC.
HST HOST HOTELS & RESORTS INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
ORLY O'REILLY AUTOMOTIVE INC.
PK PARK HOTELS & RESORTS INC.
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
BKNG BOOKING HOLDINGS INC.
LYFT LYFT
HOV HOVNANIAN ENTERPRISES INC. CLASS A
ZM ZOOM VIDEO COMMUNICATIONS INC. CLASS A
UBER UBER TECHNOLOGIES INC.
SMCI SUPER MICRO COMPUTER
DASH INC.
ABNB DOORDASH
STX AIRBNB INC. CLASS A
GFS SEAGATE TECHNOLOGY HLDGS PLC
YOU GLOBALFOUNDRIES INC
MXL-US CLEAR SECURE INC
MAXLINEAR
INC.
- Jay Kornreich
- Richard Anderson
Axsome Therapeutics Announces SYMBRAVO® (meloxicam and rizatriptan) Ac...
Axsome Therapeutics Announces SYMBRAVO® (meloxicam and rizatriptan) Achieves Primary Endpoint in the EMERGE Phase 3 Trial in Migraine Patients Experiencing Inadequate Response to Oral CGRP Inhibitors SYMBRAVO demonstrated statistically significantly greater migraine treatment response compared to prior treatment with an oral CGRP inhibitor (p
Ryman Hospitality Properties, Inc. Reports Fourth Quarter and Full Yea...
Ryman Hospitality Properties, Inc. Reports Fourth Quarter and Full Year 2024 Results NASHVILLE, Tenn., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Ryman Hospitality Properties, Inc. (NYSE: RHP), a lodging real estate investment trust (“REIT”) specializing in group-oriented, destination hotel assets in urban and resort markets, today reported financial results for the three and twelve months ended December 31, 2024. Fourth Quarter 2024 Highlights and Recent Developments: The Company reported all-time quarterly record consolidated revenue of $647.6 million, driven by all-time quarterly record Hospi...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.